Melinta Therapeutics Presents Updates on the Pyrrolocytosine Compound RX-P2382 against ESKAPE Pathogens at ECCMID 2018

NEW HAVEN, Conn., April 23, 2018 (GLOBE NEWSWIRE) — Melinta Therapeutics, Inc. (NASDAQ:MLNT), a commercial-stage company discovering, developing and commercializing novel antibiotics to treat serious bacterial infections, presented findings at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) meeting highlighting data for RX-P2382, an advanced lead investigational compound from the newly developed pyrrolocytosine class. Pyrrolocytosines were specifically designed by Melinta to target previously untapped binding sites on bacterial ribosomes and optimized for activity against today’s “superbugs”.